Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Chungping Yu, Jennie Garcia-Olivares, Shawn Candler, Stefan Schwabe & Vladimir Maletic. (2020) New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. Journal of Experimental Pharmacology 12, pages 285-300.
Read now
Read now
Ann Childress, Asmara Hoo-Cardiel & Peter Lang. (2020) Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents. Expert Opinion on Pharmacotherapy 21:4, pages 417-426.
Read now
Read now
Articles from other publishers (16)
Eric Konofal, Michel Lecendreux, Jean-Charles Bizot, Anh-Tuan Lormier & Bruno Figadère. (2024) NLS-3 (Levophacetoperane or (R,R) Phacetoperane): A Reverse Ester
of Methylphenidate: A Literature Review. Current Medicinal Chemistry 31:9, pages 1069-1081.
Crossref
Crossref
Hildur Sóley Sveinsdóttir, Christian Christensen, Haraldur Þorsteinsson, Perrine Lavalou, Matthew O. Parker, Alena Shkumatava, William H. J. Norton, Emile Andriambeloson, Stéphanie Wagner & Karl Ægir Karlsson. (2022) Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD. Neuropsychopharmacology 48:8, pages 1155-1163.
Crossref
Crossref
Samuele Cortese, Katherine McGinn, Mikkel Højlund, Alan Apter, Celso Arango, Immaculada Baeza, Tobias Banaschewski, Jan Buitelaar, Josefina Castro-Fornieles, David Coghill, David Cohen, Edna Grünblatt, Pieter J. Hoekstra, Anthony James, Pia Jeppesen, Péter Nagy, Anne Katrine Pagsberg, Mara Parellada, Antonio M. Persico, Diane Purper-Ouakil, Veit Roessner, Paramala Santosh, Emily Simonoff, Dejan Stevanovic, Argyris Stringaris, Benedetto Vitiello, Susanne Walitza, Abraham Weizman, Tamar Wohlfarth, Ian C.K. Wong, Gil Zalsman, Alessandro Zuddas, Carmen Moreno, Marco Solmi & Christoph U. Correll. (2023) The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications. Neuroscience & Biobehavioral Reviews 149, pages 105149.
Crossref
Crossref
Edmund J.S. Sonuga‐Barke, Stephen P. Becker, Sven Bölte, Francisco Xavier Castellanos, Barbara Franke, Jeffrey H. Newcorn, Joel T. Nigg, Luis Augusto Rohde & Emily Simonoff. (2022)
Annual Research Review: Perspectives on progress in
ADHD
science – from characterization to cause
. Journal of Child Psychology and Psychiatry 64:4, pages 506-532.
Crossref
Crossref
Julio Rodríguez-Lavado, Jazmín Alarcón-Espósito, Michael Mallea & Alejandro Lorente. (2022) A New Paradigm Shift in Antidepressant Therapy: From Dual-action
to Multitarget-directed Ligands. Current Medicinal Chemistry 29:29, pages 4896-4922.
Crossref
Crossref
Yang Yang, Mechelle M. Lewis, Lan Kong & Richard B. Mailman. (2022)
A Dopamine D
1
Agonist Versus Methylphenidate in Modulating Prefrontal Cortical Working Memory
. Journal of Pharmacology and Experimental Therapeutics 382:2, pages 88-99.
Crossref
Crossref
Jeffrey H. Newcorn, Beth Krone & Ralf W. Dittmann. (2022) Nonstimulant Treatments for ADHD. Child and Adolescent Psychiatric Clinics of North America 31:3, pages 417-435.
Crossref
Crossref
Andrew J. Cutler, Gregory W. Mattingly, Rakesh Jain & Welton O’Neal. (2020) Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectrums 27:2, pages 199-207.
Crossref
Crossref
Ameanté Payen, Michelle J. Chen, T. Grace Carter, Ryan P. Kilmer & Jeanette M. Bennett. (2022) Childhood ADHD, Going Beyond the Brain: A Meta-Analysis on Peripheral Physiological Markers of the Heart and the Gut. Frontiers in Endocrinology 13.
Crossref
Crossref
Konstantin Mechler, Tobias Banaschewski, Sarah Hohmann & Alexander Häge. (2022) Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacology & Therapeutics 230, pages 107940.
Crossref
Crossref
Rachel Riera, Rafael Leite Pacheco, Ângela Maria Bagattini & Ana Luiza Cabrera Martimbianco. (2021) Efficacy and safety of therapeutic use of cannabis derivatives and their synthetic analogs: Overview of systematic reviews. Phytotherapy Research 36:1, pages 5-21.
Crossref
Crossref
Samuele Cortese, Jeffrey H. Newcorn & David Coghill. (2021) A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). CNS Drugs 35:10, pages 1035-1051.
Crossref
Crossref
Yu-Shu HuangChin-Bin YehChin-Hung ChenChi-Yung ShangSusan Shur-Fen Gau. (2021) A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 31:3, pages 164-178.
Crossref
Crossref
Takuya Saito, Yushiro Yamashita, Akemi Tomoda, Takashi Okada, Hideo Umeuchi, Saki Iwamori, Satoru Shinoda, Akiko Mizuno-Yasuhira, Hidetoshi Urano, Izumi Nishino & Kazuhiko Saito. (2020) Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder. BMC Psychiatry 20:1.
Crossref
Crossref
W. Retz, P. Retz-Junginger, S. Davydenko & M. Rösler. (2020) Medikamentöse Therapie der Aufmerksamkeitsdefizit‑/Hyperaktivitätsstörung im ErwachsenenalterPharmacotherapy of attention deficit hyperactivity disorder in adults. Der Nervenarzt 91:7, pages 583-590.
Crossref
Crossref
Harika M. Reddy, Joshua S. Poole, Gerald A. Maguire & Stephen M. Stahl. (2020) New Medications for Neuropsychiatric Disorders. Psychiatric Clinics of North America 43:2, pages 399-413.
Crossref
Crossref